Go Pro
→ Buffett's Final Warning: 'The Dollar Is Going to Hell' (From Decentralized Masters) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
$1.94
+2.4%		$1.51
$0.84
▼
$2.68
$9.34M0.23129,094 shs181,854 shs
BioAtla, Inc. stock logo
BCAB
BioAtla
$1.85
+3.4%		$2.81
$1.07
▼
$71.50
$3.08M0.7157,135 shs8,654 shs
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.01
+7.0%		$1.51
$0.91
▼
$46.50
$7.07M2.852.50 million shs253,552 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$1.75
-0.8%		$3.39
$1.50
▼
$39.92
$7.75M2.961,516 shs52,654 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
0.00%+9.88%+21.15%+54.92%-21.25%
BioAtla, Inc. stock logo
BCAB
BioAtla
0.00%+19.33%-43.71%-50.55%-94.24%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
0.00%-15.56%-21.84%-69.69%-92.80%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
0.00%-13.48%-21.21%-68.87%-94.48%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
$1.94
+2.4%		$1.51
$0.84
▼
$2.68
$9.34M0.23129,094 shs181,854 shs
BioAtla, Inc. stock logo
BCAB
BioAtla
$1.85
+3.4%		$2.81
$1.07
▼
$71.50
$3.08M0.7157,135 shs8,654 shs
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.01
+7.0%		$1.51
$0.91
▼
$46.50
$7.07M2.852.50 million shs253,552 shs
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
$1.75
-0.8%		$3.39
$1.50
▼
$39.92
$7.75M2.961,516 shs52,654 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
0.00%+9.88%+21.15%+54.92%-21.25%
BioAtla, Inc. stock logo
BCAB
BioAtla
0.00%+19.33%-43.71%-50.55%-94.24%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
0.00%-15.56%-21.84%-69.69%-92.80%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
0.00%-13.48%-21.21%-68.87%-94.48%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
2.00
Hold$28.001,347.03% Upside
BioAtla, Inc. stock logo
BCAB
BioAtla
2.00
Hold$200.0010,710.81% Upside
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.50
Moderate Buy$67.506,569.96% Upside
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
2.20
Hold$64.003,557.14% Upside

Current Analyst Ratings Breakdown

Latest BCAB, SKYE, ALZN, and CODX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/8/2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/31/2026
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
8/31/2026
BioAtla, Inc. stock logo
BCAB
BioAtla
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
8/27/2026
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/18/2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/17/2026
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
8/3/2026
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
7/20/2026
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (E+) ➝ Sell (E)
7/10/2026
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/29/2026
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
N/AN/AN/AN/A$0.19 per shareN/A
BioAtla, Inc. stock logo
BCAB
BioAtla
$8.50M0.36N/AN/A($28.51) per share-0.06
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$721.39K9.79N/AN/A$9.14 per share0.11
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/A$5.00 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
-$8.77M-$2.30N/AN/AN/AN/A-277.88%-184.20%12/8/2026 (Estimated)
BioAtla, Inc. stock logo
BCAB
BioAtla
-$59.61M-$25.45N/AN/AN/AN/AN/A-289.67%11/12/2026 (Estimated)
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$46.90M-$10.32N/AN/AN/A-6,531.77%-210.99%-174.97%11/5/2026 (Estimated)
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$55.92M-$10.16N/AN/AN/AN/A-329.08%-201.79%N/A

Latest BCAB, SKYE, ALZN, and CODX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/10/2026Q1 2027
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
-$0.56-$0.68-$0.12-$0.68N/AN/A
8/14/2026Q2 2026
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
-$0.29-$0.27+$0.02-$2.4550N/AN/A
8/13/2026Q2 2026
BioAtla, Inc. stock logo
BCAB
BioAtla
-$8.50$0.14+$8.64$0.27$6.50 million$6.50 million
8/13/2026Q2 2026
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$3.00-$1.46+$1.54-$1.46$0.13 million$0.17 million
7/22/2026Q4 2026
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
-$0.67-$0.74-$0.07-$0.74N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
N/AN/AN/AN/AN/A
BioAtla, Inc. stock logo
BCAB
BioAtla
N/AN/AN/AN/AN/A
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/AN/AN/AN/AN/A
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
N/A
3.01
3.01
BioAtla, Inc. stock logo
BCAB
BioAtla
N/A
0.20
0.20
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A
1.81
1.52
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
N/A
0.95
0.95

Institutional Ownership

CompanyInstitutional Ownership
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
49.61%
BioAtla, Inc. stock logo
BCAB
BioAtla
77.23%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
14.99%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
21.09%

Insider Ownership

CompanyInsider Ownership
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
1.39%
BioAtla, Inc. stock logo
BCAB
BioAtla
9.34%
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.30%
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
6.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alzamend Neuro, Inc. stock logo
ALZN
Alzamend Neuro
64.83 million4.76 millionNo Data
BioAtla, Inc. stock logo
BCAB
BioAtla
601.67 million1.51 millionOptionable
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
1156.98 million6.82 millionNo Data
Skye Bioscience, Inc. stock logo
SKYE
Skye Bioscience
124.43 million4.15 millionOptionable

Recent News About These Companies

Insider Selling: Skye Bioscience (NASDAQ:SKYE) Major Shareholder Sells $64,733.72 in Stock
September 21 at 4:38 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036520
Skye Bioscience (NASDAQ:SKYE) Director Sells $64,733.72 in Stock
September 21 at 4:38 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31036510
5Am Partners Vii, Llc Sells 33,892 Shares of Skye Bioscience (NASDAQ:SKYE) Stock
September 19 at 7:07 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-skye-insider-buying-and-selling-2026-09-19/
Skye Bioscience average analyst price target raised 10.29% to $61.20
September 15, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/skye-bioscience-average-analyst-price-target-raised-10-29-to-61-20/ar-AA2ch1eV
Skye Bioscience (SKYE) shares rise 6% after hours: Here's what's driving the move
August 26, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/skye-bioscience-skye-shares-rise-6-after-hours-heres-whats-driving-the-move/ar-AA2aWZZE
Skye Bioscience (NASDAQ:SKYE) Director Sells 68,140 Shares
August 21, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-skye-insider-buying-and-selling-2026-08-21/
Skye Bioscience, Inc. (SKYE) M&A Call Prepared Remarks Transcript
August 14, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936945-skye-bioscience-inc-skye-m-and-a-call-prepared-remarks-transcript
Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings
August 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345392/0/en/skye-bioscience-and-redx-pharma-announce-transaction-agreement-and-125-million-in-financings.html
Pomerantz LLP Commences Class Action Against Skye Bioscience, Inc. – SKYE
July 12, 2026  |  natlawreview.comN
Cadrenal Therapeutics Names Sharp Interim CFO
June 29, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/cadrenal-therapeutics-names-sharp-interim-cfo-d989c809
Skye Bioscience Expands Authorized Shares After Shareholder Approval
May 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/skye-bioscience-expands-authorized-shares-after-shareholder-approval?utm_source=marketbeat.com&utm_medium=referral
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
May 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/20/3298335/0/en/skye-announces-cohort-review-committee-approved-opening-of-cohort-2-based-on-favorable-safety-data-from-first-four-participants-treated-in-cohort-1.html
Skye Bioscience (SKYE) price target decreased by 11.48% to 7.87
May 14, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/skye-bioscience-skye-price-target-decreased-by-1148-to-787/ar-AA23efXu
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Coherus Biosciences (CHRS), Moderna (MRNA) and Skye Bioscience (SKYE)
May 14, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MRNA/pressreleases/1894362/analysts-opinions-are-mixed-on-these-healthcare-stocks-coherus-biosciences-chrs-moderna-mrna-and-skye-bioscience-skye/
Skye Bioscience, Inc.: Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
May 14, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68466082-skye-bioscience-inc-skye-bioscience-reports-first-quarter-2026-financial-results-and-business-update-399.htm
Pomerantz LLP Files Investor Lawsuit Against Skye Bioscience, Inc. – SKYE
May 13, 2026  |  natlawreview.comN
Skye Bioscience Initiates CBeyond™ Expansion Study (Part C) with Planned Review on May 18, 2026
May 12, 2026  |  quiverquant.comQ
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
May 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/12/3293281/0/en/update-skye-bioscience-reports-first-quarter-2026-financial-results-and-business-update.html
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
May 11, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/11/3292287/0/en/skye-bioscience-reports-first-quarter-2026-financial-results-and-business-update.html
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm
April 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/22/3279089/0/en/kuehn-law-encourages-investors-of-skye-bioscience-inc-to-contact-law-firm.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alzamend Neuro stock logo

Alzamend Neuro NASDAQ:ALZN

$1.94 +0.05 (+2.38%)
As of 02:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

BioAtla stock logo

BioAtla NASDAQ:BCAB

$1.85 +0.06 (+3.35%)
As of 01:13 PM Eastern

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.

Co-Diagnostics stock logo

Co-Diagnostics NASDAQ:CODX

$1.01 +0.07 (+7.01%)
As of 02:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Skye Bioscience stock logo

Skye Bioscience NASDAQ:SKYE

$1.75 -0.02 (-0.85%)
As of 02:59 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas